TITLE

Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy

PUB. DATE
September 2007
SOURCE
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p47
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a clinical trial that states that vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy. Details related to the methodology, the randomized placebo-controlled trial-design, patients, and the main results are presented.
ACCESSION #
27029979

 

Related Articles

  • Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy: COMMENTARY. Basu, Ananda // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p47 

    The article offers the author's comments on a clinical trial that states that vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy. While the author acknowledges the positive results, he cautions that the dipeptidyl peptidase or...

  • Saxagliptin. Dhillon, Sohita; Weber, Juliane // Drugs;2009, Vol. 69 Issue 15, p2103 

    â–´Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-l (GLP- 1) and glucose-dependent insulinotropic polypeptide. This increases GLP-l levels, stimulates...

  • New from NPG.  // Nature Medicine;Apr2013, Vol. 19 Issue 4, p417 

    This section offers medical research news briefs on topics such as functional receptor role of dipeptidyl peptidase 4 in the new human coronavirus EMC, blocking function of ATP-competitive kinase inhibitors, and identification of new loci associated with age-related macular degeneration (AMD).

  • Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review. Wong, Martin C. S.; Wang, Harry H. X.; Kwan, Mandy W. M.; Zhang, Daisy D. X.; Liu, Kirin Q. L.; Chan, Sky W. M.; Fan, Carmen K. M.; Fong, Brian C. Y.; Li, Shannon T. S.; Griffiths, Sian M. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug...

  • Investigational DPP-IV inhibitor at various doses reduced HbA1c in type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p31 

    The article reports on a study which found that an investigational, once-weekly dipeptidyl peptidase-intravenous (DPP-IV) inhibitor significantly lowered HbA1c in type 2 diabetes.

  • Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes. Kirk, Julienne K.; Oldham, Elizabeth C. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2008, Vol. 2 Issue 3, p162 

    The clinical efficacy and tolerability of dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes is supported by published clinical trials. Primary literature and review articles were obtained via a Pubmed search (2002-2008) using the search terms diabetes, sitagliptin,...

  • Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. MONAMI, MATTEO; DICEMBRINI, ILARIA; ANTENORE, ALESSANDRO; MANNUCCI, EDOARDO // Diabetes Care;Nov2011, Vol. 34 Issue 11, p2474 

    OBJECTIVE--Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far....

  • Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis. Cheng, Dongsheng; Fei, Yang; Liu, Yumei; Li, Junhui; Chen, Yuqiang; Wang, Xiaoxia; Wang, Niansong // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Objective: To perform a systematic review and meta-analysis regarding the efficacy and safety of dipeptidyl peptidase-4 (DDP-4) inhibitors (“gliptins”) for the treatment of type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment. Methods: All available...

  • Erratum.  // Diabetes Care;Jan2014, Vol. 37 Issue 1, following p312 

    A correction to the article "Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials" in the 2014 issue is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics